Indegene Reports Strong Q2 FY26 Results with 17% YoY Revenue Growth

Indegene Limited , a tech-native life sciences specialist, has announced robust financial results for the second quarter of fiscal year 2026, demonstrating continued growth and strategic expansion.

Financial Highlights

Indegene reported a significant year-over-year revenue growth of 17.1%, with revenue from operations reaching INR 8,042.00 million for Q2 FY26. This marks the fourth consecutive quarter of strong growth for the company. In USD terms, the revenue growth stood at 12.4% year-over-year.

The company maintained a healthy profitability profile with an adjusted EBITDA of INR 1,461.00 million, representing an 18.2% margin. Profit after tax (PAT) for the quarter was INR 1,021.00 million, with a PAT margin of 12.7%.

Segment Performance

Indegene's core segments, Enterprise Commercial Solutions (ECS) and Enterprise Medical Solutions (EMS), showed strong performance:

ECS revenue grew to INR 4,874.00 million, up 26.2% year-over-year
EMS revenue increased to INR 2,242.00 million, up 13.4% year-over-year

The Brand Activation segment (formerly Omnichannel Activation) experienced a decline of 15.8% quarter-over-quarter, reflecting shifts in market dynamics.

Strategic Acquisitions

Indegene announced two strategic acquisitions to enhance its capabilities:

BioPharm: A US-based specialized marketing services agency, acquired for USD 104.00 million. This acquisition aims to strengthen Indegene's commercialization portfolio with AdTech capabilities.
WARN & Co.: A UK-based transformation consulting firm, acquired to enhance Indegene's expertise in business transformation consulting.

Operational Highlights

Active client relationships increased to 76, up from 70 in the previous quarter
The company maintained 40 clients with over $1 million in revenue
Total employee count reached 5,245, with 4,523 in delivery roles

Management Commentary

Manish Gupta, Chairman and CEO of Indegene, stated, "We delivered strong growth for the fourth consecutive quarter, driven by continued momentum in deal wins and execution. A robust pipeline generation points to a positive industry outlook."

Suhas Prabhu, CFO, added, "In Q2FY26, our focus was on executing our strategic priorities: from business development to delivery, especially on newer engagement models like Tectonic; from technology enablement to bring AI to clients faster; to M&A to deepen our expertise and credibility."

Future Outlook

Indegene's management expressed confidence in the company's growth trajectory, citing a robust pipeline and positive industry outlook. The focus for the upcoming quarter will be on renewals and new wins to build a solid foundation for the next calendar year.

The strategic acquisitions of BioPharm and WARN & Co. are expected to bring advanced capabilities that align with Indegene's vision and future direction, potentially opening new avenues for growth and market expansion.

With its continued focus on innovation, strategic expansion, and client-centric approach, Indegene appears well-positioned to capitalize on the evolving needs of the life sciences industry.

Key Financial Metrics (Q2 FY26)

Metric	Value (INR million)	YoY Growth
Revenue from Operations	8,042.00	17.1%
Adjusted EBITDA	1,461.00	15.3%
Profit After Tax	1,021.00	11.3%
ECS Revenue	4,874.00	26.2%
EMS Revenue	2,242.00	13.4%

Investors and stakeholders will likely watch closely how Indegene leverages its recent acquisitions and strategic initiatives to drive further growth in the coming quarters.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.29%	-0.14%	-3.85%	-1.52%	-13.92%	-5.52%

Indegene Limited , a leading healthcare tech company, has reported robust financial results for the second quarter of fiscal year 2025-26, alongside a strategic investment decision for its Irish subsidiary.

Strong Financial Performance

Indegene has demonstrated significant growth in its Q2 consolidated financial results:

Metric	Q2 FY2025-26	Q2 FY2024-25	YoY Change
Net Profit	₹1.02 billion	₹917.00 million	+11.2%
Revenue	₹8.04 billion	₹6.87 billion	+17.0%
EBITDA	₹1.41 billion	₹1.26 billion	+11.9%

The company's revenue saw a substantial increase of 17% year-over-year, rising to ₹8.04 billion from ₹6.87 billion in the same quarter last year. This growth reflects Indegene's strong market position and effective business strategies.

Net profit for the quarter reached ₹1.02 billion, marking an 11.2% increase from ₹917.00 million in the corresponding period of the previous year. This improvement in profitability underscores the company's operational efficiency and cost management.

EBITDA also showed positive growth, increasing by 11.9% to ₹1.41 billion from ₹1.26 billion year-over-year. However, it's worth noting that the EBITDA margin experienced a slight decline, moving from 18.36% to 17.48%.

Strategic Investment in Irish Subsidiary

In a significant move to strengthen its global presence, Indegene's board has approved an investment of up to €8.5 million in equity shares of Indegene Ireland Limited, its wholly owned subsidiary. This investment is expected to support the subsidiary's capital expenditure requirements and business expansion plans.

The company stated that the investment would be made in one or more tranches, with the exact number of shares and applicable share premium to be finalized based on a valuation report from a registered valuer.

Outlook

Indegene's strong financial performance and strategic investment decisions indicate the company's commitment to growth and global expansion. The investment in its Irish subsidiary may enhance Indegene's capabilities in providing solutions for analytics, technology, and commercial, medical, regulatory, and safety services to life science and healthcare organizations in the European market.

As Indegene continues to navigate the dynamic healthcare technology landscape, investors and industry observers will be keen to see how these strategic moves translate into long-term value creation and market positioning.